Alnylam Pharmaceuticals Ownership

ALNY Stock  USD 299.17  15.83  5.59%   
Alnylam Pharmaceuticals holds a total of 129.46 Million outstanding shares. The majority of Alnylam Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alnylam Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alnylam Pharmaceuticals. Please pay attention to any change in the institutional holdings of Alnylam Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million twenty-two thousand seven hundred ten invesors are currently shorting Alnylam Pharmaceuticals expressing very little confidence in its future performance.
 
Shares in Circulation  
First Issued
2009-03-31
Previous Quarter
129 M
Current Value
128 M
Avarage Shares Outstanding
86.6 M
Quarterly Volatility
30.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Alnylam Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Alnylam Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Alnylam Stock Ownership Analysis

About 97.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.18. Alnylam Pharmaceuticals had not issued any dividends in recent years. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1665 people. For more info on Alnylam Pharmaceuticals please contact MD MBA at 617 551 8200 or go to https://www.alnylam.com.
Besides selling stocks to institutional investors, Alnylam Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Alnylam Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Alnylam Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Alnylam Pharmaceuticals Quarterly Liabilities And Stockholders Equity

4.24 Billion

Alnylam Pharmaceuticals Insider Trades History

Roughly 4.0% of Alnylam Pharmaceuticals are currently held by insiders. Unlike Alnylam Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Alnylam Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Alnylam Pharmaceuticals' insider trades
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Alnylam Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Alnylam Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alnylam Pharmaceuticals backward and forwards among themselves. Alnylam Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Alnylam Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
T. Rowe Price Associates, Inc.2024-12-31
3.3 M
Norges Bank2024-12-31
2.5 M
Jpmorgan Chase & Co2024-12-31
2.3 M
Geode Capital Management, Llc2024-12-31
2.2 M
American Century Companies Inc2024-12-31
1.6 M
Groupama Asset Management2024-12-31
1.5 M
Orbis Allan Gray Ltd2024-12-31
1.5 M
Capital Research & Mgmt Co - Division 32024-12-31
1.4 M
Winslow Capital Management, Llc2024-12-31
M
Capital World Investors2024-12-31
16.6 M
Fmr Inc2024-12-31
13.5 M
Note, although Alnylam Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alnylam Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alnylam Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alnylam Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alnylam Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Garg Pushkal over a month ago
Disposition of 25000 shares by Garg Pushkal of Alnylam Pharmaceuticals at 88.95 subject to Rule 16b-3
 
Kevin Fitzgerald over a month ago
Disposition of 6667 shares by Kevin Fitzgerald of Alnylam Pharmaceuticals at 97.72 subject to Rule 16b-3
 
Sharp Phillip A over a month ago
Disposition of 11250 shares by Sharp Phillip A of Alnylam Pharmaceuticals at 131.21 subject to Rule 16b-3
 
Pyott David E I over three months ago
Disposition of 17560 shares by Pyott David E I of Alnylam Pharmaceuticals at 88.95 subject to Rule 16b-3
 
Kevin Fitzgerald over six months ago
Disposition of 6667 shares by Kevin Fitzgerald of Alnylam Pharmaceuticals at 97.72 subject to Rule 16b-3
 
Ausiello Dennis A over six months ago
Disposition of 11250 shares by Ausiello Dennis A of Alnylam Pharmaceuticals at 131.21 subject to Rule 16b-3
 
Franchini Indrani Lall over six months ago
Disposition of 269 shares by Franchini Indrani Lall of Alnylam Pharmaceuticals at 172.38 subject to Rule 16b-3
 
Franchini Indrani Lall over a year ago
Disposition of 878 shares by Franchini Indrani Lall of Alnylam Pharmaceuticals subject to Rule 16b-3
 
Akshay Vaishnaw over a year ago
Acquisition by Akshay Vaishnaw of 5082 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
 
Akshay Vaishnaw over a year ago
Exercise or conversion by Akshay Vaishnaw of 30913 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
 
Akshay Vaishnaw over a year ago
Acquisition by Akshay Vaishnaw of 5312 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
 
Akshay Vaishnaw over a year ago
Exercise or conversion by Akshay Vaishnaw of 30913 shares of Alnylam Pharmaceuticals subject to Rule 16b-3

Alnylam Pharmaceuticals Outstanding Bonds

Alnylam Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alnylam Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alnylam bonds can be classified according to their maturity, which is the date when Alnylam Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Alnylam Pharmaceuticals Corporate Filings

8K
21st of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of March 2025
Other Reports
ViewVerify
F4
5th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.